Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Genuine Parts Q3 Adjusted Earnings, Net Sales Rise; Narrows 2026 Adjusted EPS Outlook

Genuine Parts Q3 Adjusted Earnings, Net Sales Rise; Narrows 2026 Adjusted EPS Outlook

MT newswireMT newswire2026/10/20 11:10
07:10 AM EDT, 10/20/2026 (MT Newswires) -- Genuine Parts (GPC) reported Q3 adjusted earnings Tuesday of $2.07 per diluted share, up from $1.98 a year earlier. Analysts polled by FactSet expected $2.04. Net sales for the quarter ended Sept. 30 were $6.52 billion, compared with $6.26 billion a year earlier. Analysts expected $6.49 billion. For 2026, the company now expects adjusted EPS of $7.50 to $7.75 per share, compared with its prior guidance of $7.50 to $8. Analysts expect $7.74. Genuine Parts said it continues to expect full-year sales growth of 3% to 5.5%. Analysts expect $25.55 billion.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Profit surges 7-fold, revenue breaks 100 trillions for the first time: SK hynix (SKHY.US) responds to AI bubble concerns with record-breaking quarterly report

SK Hynix reported an operating profit of 83.3 trillion won for the third quarter, surpassing expectations, and announced shareholder returns of approximately 100 trillion won within the year.

智通财经•2026/10/28 00:37
Profit surges 7-fold, revenue breaks 100 trillions for the first time: SK hynix (SKHY.US) responds to AI bubble concerns with record-breaking quarterly report

AstraZeneca (AZN.US) CEO hints at entry into cancer vaccines: years of experience with mRNA technology and more updates expected in the coming months

AstraZeneca is considering developing a cancer vaccine, with the CEO stating that the company has already accumulated experience in mRNA technology. Personalized vaccines have reduced the recurrence rate of melanoma by 42%, but cost and production capacity remain obstacles to broader adoption.

智通财经•2026/10/28 00:17
AstraZeneca (AZN.US) CEO hints at entry into cancer vaccines: years of experience with mRNA technology and more updates expected in the coming months